Listing 7.10 Bone Marrow Failure Disorders in 2026: Full Walkthrough of the Two-Paragraph Test for Aplastic Anemia, Myelodysplastic Syndromes, Myelofibrosis, and Granulocytopenia, Why 7.10A Three Hospitalizations and 7.10B Every Six Week Transfusion Are Not Interchangeable, and When to Move to 7.17 or 7.18 Instead

By Anthony Albert, Benefits Research Director. Published July 23, 2026.

Listing 7.10 is the SSA rule for bone marrow failure disorders. It replaced the old Listings 7.03, 7.04, and 7.06 in the May 2015 rewrite of Section 7.00. Four diagnostic categories fit here: aplastic anemia, myelodysplastic syndromes (MDS), myelofibrosis, and granulocytopenia. Sideroblastic anemia and paroxysmal nocturnal hemoglobinuria (PNH) can also fit when the picture is dominated by marrow failure rather than by hemolysis.

The listing has two paragraphs, A and B. You meet 7.10 by hitting either paragraph. This article walks through both criteria in detail, explains why they are not interchangeable (they measure different clinical realities), covers the diagnostic evidence SSA actually requires, and shows when a 7.10 claim should be moved to 7.17 (if you get a transplant), 7.18 (if you have repeated complications short of the numeric thresholds), or a body system referral. Four worked cases at the end.

The Listing 7.10 Text

Notice the structure. 7.10A counts hospitalizations and applies to any bone marrow failure disorder. 7.10B specifically names MDS and aplastic anemia, and it counts transfusion frequency. They measure different things. A patient with severe neutropenia and recurrent infections can hit 7.10A without ever being transfusion dependent. A patient with pure red cell aplasia can hit 7.10B without ever being hospitalized.

What Bone Marrow Failure Disorders Are Covered

Aplastic anemia

Pancytopenia with hypocellular bone marrow, absent significant dysplasia or fibrosis. Severe aplastic anemia (SAA) is defined by two of three criteria: absolute neutrophil count under 500, platelets under 20,000, or reticulocyte count under 60,000. Very severe aplastic anemia has neutrophils under 200. Causes include idiopathic (most common), drug-induced, viral (hepatitis-associated), radiation, and inherited (Fanconi anemia). First-line treatment is HSCT for eligible patients or immunosuppressive therapy (ATG plus cyclosporine, and increasingly eltrombopag) for those without a matched donor.

Myelodysplastic syndromes (MDS)

Clonal marrow disorders with ineffective hematopoiesis and increased risk of transformation to acute myeloid leukemia. Classified by 2022 WHO criteria into MDS with low blasts (MDS-LB), MDS with increased blasts (MDS-EB1 with 5 to 9 percent blasts, MDS-EB2 with 10 to 19 percent blasts), MDS with defined genetic abnormalities (SF3B1-mutated, del(5q), TP53-mutated, biallelic TP53), and MDS-fibrotic. IPSS-R risk stratification (revised International Prognostic Scoring System) predicts survival and transformation risk. Treatments include supportive care, hypomethylating agents (azacitidine, decitabine), lenalidomide for del(5q), luspatercept for ring sideroblasts, and HSCT for high-risk patients.

Myelofibrosis

Clonal myeloproliferative disorder with progressive marrow fibrosis, extramedullary hematopoiesis, and cytopenia. Primary myelofibrosis (PMF) or secondary (post-polycythemia vera or post-essential thrombocythemia). Diagnostic criteria per 2022 WHO include marrow reticulin/collagen fibrosis, driver mutation (JAK2, CALR, MPL), and clinical or laboratory findings including anemia, splenomegaly, elevated LDH, leukoerythroblastic peripheral smear. Treatment includes JAK inhibitors (ruxolitinib, fedratinib, pacritinib, momelotinib), supportive transfusions, and HSCT for eligible patients.

Granulocytopenia

Persistent low neutrophil count with recurrent infections. Includes congenital forms (severe congenital neutropenia due to ELANE, HAX1, WAS mutations), cyclic neutropenia, chronic idiopathic neutropenia, and autoimmune neutropenia. Treatment includes G-CSF (filgrastim, pegfilgrastim) and prophylactic antibiotics. Meets 7.10A when neutropenia leads to recurrent hospitalization for infection.

PNH and other

Paroxysmal nocturnal hemoglobinuria (PNH) has both hemolytic and marrow failure features. When the marrow failure dominates, evaluate under 7.10. When hemolysis and thrombosis dominate, evaluate under 7.05 (hemolytic) or 7.08 (thrombosis). Treatments include eculizumab, ravulizumab, danicopan, iptacopan (2024 FDA approval).

7.10A in Detail: Three Hospitalizations

You meet 7.10A with:

1. At least three hospitalizations within a 12 month period
2. Complications of bone marrow failure as the reason for each hospitalization (not unrelated conditions)
3. At least 30 days apart between hospitalizations
4. Each hospitalization at least 48 hours, including ED time immediately before admission

What counts as a complication of bone marrow failure

The listing does not enumerate specific complications. Under 7.00E, SSA describes bone marrow failure complications as including:

• Severe infection due to neutropenia or immunosuppression (bacterial sepsis, fungal infections, viral reactivations)
• Bleeding due to thrombocytopenia (spontaneous gum bleeding, epistaxis, GI bleed, intracranial hemorrhage, hemothorax, hemarthrosis)
• Cardiac complications from severe anemia (high output CHF, angina, arrhythmia)
• Transfusion reactions requiring inpatient management (febrile non-hemolytic, hemolytic, TRALI, TACO)
• Symptomatic anemia requiring urgent transfusion in a hospital setting
• Iron overload complications from chronic transfusion (secondary hemochromatosis with cardiomyopathy, cirrhosis, endocrinopathies)
• Acute deterioration of underlying disease requiring inpatient treatment

The 30 day interval

The rule requires hospitalizations to be at least 30 days apart. Same-week readmissions do not count as two hospitalizations. If you are readmitted for a related complication within 30 days, SSA generally treats it as one continuous hospitalization for listing purposes. This can hurt claimants who have recurrent short admissions clustered together.

The 48 hour and ED rule

Each hospitalization must last 48 hours, but ED time immediately before admission counts. A 12 hour ED stay before a 40 hour inpatient admission totals 52 hours, which qualifies. A 24 hour ED observation stay without inpatient admission does not count. Ambulatory infusion visits do not count. Same-day surgery does not count. The hospital record must show the ED-to-discharge timeline. Ask hospital records for the full account.

7.10B in Detail: Every Six Week Transfusion

You meet 7.10B with:

1. Documented MDS or aplastic anemia, confirmed by bone marrow biopsy
2. Lifelong RBC transfusions, meaning transfusion dependence expected to be permanent
3. At least once every 6 weeks transfusion frequency, on average
4. Required to maintain life, meaning without transfusion the patient would die from cardiac decompensation or organ ischemia

Why this criterion is limited to MDS and aplastic anemia

7.10B specifically names MDS and aplastic anemia. Myelofibrosis patients who become transfusion dependent do not qualify under 7.10B on that criterion alone. They can qualify under 7.10A if they have recurrent hospitalizations, or under 7.18 for repeated complications with marked functional limitation. This is a narrowness in the listing text that catches some myelofibrosis claimants off guard. If you have myelofibrosis and are transfusion dependent, argue equivalence to 7.10B under 20 CFR 404.1526 based on similar clinical picture.

Transfusion frequency documentation

Blood bank transaction logs are the strongest evidence. They show every transfusion date, number of units, pre-transfusion hemoglobin, and post-transfusion hemoglobin. Ask your hematology clinic or blood bank for a complete transfusion history over the past 12 months. The 6 week interval is calculated as an average, so a patient transfused every 4 to 5 weeks meets the criterion cleanly. A patient transfused every 7 to 8 weeks does not meet on the numeric criterion but may still argue equivalence if hematology intervals are being stretched for reasons other than clinical stability (blood supply limits, patient preference to delay).

Diagnostic Requirements Under 7.00E

SSA requires diagnostic confirmation of bone marrow failure. Under 7.00E, the following are typically required:

1. Bone marrow biopsy report showing cellularity percentage, morphology, blast count, dysplasia grade, fibrosis grade, and cytogenetic findings. For MDS, IPSS-R risk categorization. For myelofibrosis, MF grade 2 or 3 per WHO criteria.
2. Complete blood count series showing persistent cytopenia. Multiple time points over at least 3 months to establish chronicity.
3. Peripheral smear report describing red cell morphology, white cell morphology, and platelet morphology.
4. Reticulocyte count to distinguish hypoproliferative (marrow failure) from destructive (hemolytic) processes.
5. Molecular testing where appropriate. For MDS: SF3B1, TP53, ASXL1, EZH2, RUNX1, SRSF2, and cytogenetics. For myelofibrosis: JAK2, CALR, MPL. For congenital marrow failure: gene panels for Fanconi anemia, dyskeratosis congenita, GATA2 deficiency, DBA, Shwachman-Diamond.
6. Ferritin and iron studies for transfusion-dependent patients to document iron overload.
7. Erythropoietin level for MDS to guide treatment and risk assessment.

SSA generally does not order consultative bone marrow biopsies. If your treating hematologist has performed the biopsy, get the pathology report into the file. If a biopsy has not been done and one is planned, delay filing until after the report is available, unless CAL flagging applies through 7.17 for planned transplantation.

When to Move to 7.17

If you receive a bone marrow or stem cell transplant for your bone marrow failure disorder, Listing 7.17 applies from the transplantation date and grants automatic 12 months of CAL-level disability. You do not need to hit 7.10A or 7.10B once 7.17 applies. A 7.10 claim in progress at the time of transplant should be updated to a 7.17 claim by submitting the transplantation record.

When to Move to 7.18

If you do not meet 7.10A (fewer than 3 hospitalizations or under 48 hours) or 7.10B (transfusion interval over 6 weeks or not MDS/aplastic anemia), Listing 7.18 is the escape valve. 7.18 requires repeated complications of a hematological disorder plus marked limitation in one of three areas: activities of daily living, social functioning, or completing tasks due to deficiencies in concentration, persistence, or pace. See our dedicated 7.18 article for full mechanics.

When to Move to a Body System Listing

If bone marrow failure has caused significant organ damage, the underlying body system may meet its own listing:

• Iron overload cardiomyopathy from chronic transfusion: Listing 4.02 chronic heart failure
• Iron overload cirrhosis: Listing 5.05 chronic liver disease
• Iron overload endocrinopathies (hypogonadism, diabetes, hypothyroidism): Section 9 endocrine referrals to appropriate listings
• Chronic kidney disease from calcineurin inhibitor toxicity (post-transplant patients): Listing 6.03 (dialysis), 6.04 (transplant), or 6.05 (CKD with complications)

Documentation Checklist

1. Bone marrow biopsy pathology report with cellularity, blast count, fibrosis grade, cytogenetics, and molecular findings
2. CBC series with differential over at least 3 months documenting persistent cytopenia
3. Peripheral smear report
4. Reticulocyte count
5. Molecular and cytogenetic testing report
6. Blood bank transfusion history over the past 12 months
7. Hospitalization records with admission notes, discharge summaries, and length of stay including ED time
8. Documentation of complications: infection cultures with sensitivities, bleeding events, transfusion reaction reports
9. Iron studies (ferritin, transferrin saturation) if chronic transfusion
10. Cardiac MRI T2* if iron overload suspected
11. Treating hematologist RFC or narrative statement

Four Worked Cases

Case One, Terrance, 55, Ohio

Terrance has MDS-EB2 (12 percent blasts, IPSS-R high risk) diagnosed via bone marrow biopsy 14 months ago. He has been transfused every 3 to 4 weeks for 10 months, verified by blood bank records showing 15 transfusion events with pre-transfusion hemoglobin ranging 6.8 to 7.9 g/dL. Cytogenetics show del(5q) with additional abnormalities. He meets 7.10B on transfusion frequency and MDS diagnosis. SSDI approved.

Case Two, Nina, 41, Arizona

Nina has severe aplastic anemia diagnosed 8 months ago after biopsy showing 10 percent cellularity and no dysplasia. She has been hospitalized three times: once for neutropenic fever with methicillin-resistant Staphylococcus aureus bacteremia lasting 8 days, once for platelet count 3,000 with epistaxis and mucosal bleeding lasting 4 days, and once for transfusion reaction with respiratory compromise lasting 3 days. All three hospitalizations more than 30 days apart, all over 48 hours. She meets 7.10A. SSDI approved. If she receives HSCT (matched unrelated donor identified), 7.17 will apply from the transplantation date for 12 months.

Case Three, Rashad, 63, Michigan

Rashad has primary myelofibrosis (MF grade 3, JAK2 V617F positive) with progressive anemia and transfusion dependence every 4 weeks. Bone marrow biopsy confirms diagnosis. Splenomegaly with abdominal discomfort but no hospitalization in past 12 months. He does not meet 7.10A (no qualifying hospitalizations). He does not meet 7.10B on the strict text because myelofibrosis is not named. He files under equivalence to 7.10B, citing that his clinical picture (transfusion dependence, marrow failure, expected to be lifelong) is medically equivalent to MDS with the same transfusion pattern. He also files under 7.18 with documented marked limitation in ADL from fatigue and abdominal pain. ALJ approves under equivalence to 7.10B plus 7.18 alternative.

Case Four, Sofia, 32, Texas

Sofia has severe congenital neutropenia (ELANE mutation) with baseline ANC 200. In the past 12 months she has been hospitalized 4 times for bacterial infections: gram-negative bacteremia (7 days), invasive fungal pneumonia (14 days), cellulitis with sepsis (5 days), and Pseudomonas pneumonia (11 days). All admissions more than 30 days apart, all over 48 hours. She meets 7.10A. SSDI approved. G-CSF therapy continues, but breakthrough infections show inadequate response.

Denial Counters

Denial reason: only 2 hospitalizations in 12 months

7.10A requires 3. Options include: refile after a third hospitalization occurs, argue equivalence with severe complications documented outside hospital (e.g., home IV antibiotics for what would otherwise be inpatient care), or move to 7.18 with functional criteria.

Denial reason: hospitalization was 40 hours, not 48

Check ED time. ED hours immediately before admission count. Ask the hospital for the full ED-to-discharge log. A 10 hour ED stay before a 40 hour inpatient stay totals 50 hours, which qualifies.

Denial reason: transfusion frequency is every 7 weeks, not 6

7.10B requires every 6 weeks on average. If the average across 12 months is 6.5 to 7 weeks, argue equivalence with treating hematologist statement that clinically the patient requires every 4 to 5 weeks but blood bank supply constraints have stretched intervals. Also argue 7.18 with functional criteria if fatigue and organ hypoxia symptoms are documented.

Denial reason: myelofibrosis or PNH is not named in 7.10B

Correct. 7.10B names only MDS and aplastic anemia. File under equivalence per 20 CFR 404.1526 based on similar clinical picture (marrow failure, transfusion dependence, lifelong requirement, clinical severity). Also consider 7.10A on hospitalization criteria or 7.18 on repeated complications with functional limitation.

State Considerations

Hematology consultation availability varies by state. Higher-density hematology states include New York, Massachusetts, Pennsylvania, Ohio, and California, where academic centers with MDS Center of Excellence designations shorten diagnostic workup timelines. Rural states like Montana, Wyoming, and Idaho often require travel to regional centers for bone marrow biopsy interpretation.

Medicaid coverage of hematology diagnostics is universal in expansion states. Non-expansion states may have gaps that delay biopsy scheduling and molecular testing, which delays SSDI documentation.

Related Blue Book Reading

• Listing 7.05 Hemolytic Anemias
• Listing 7.08 Disorders of Thrombosis and Hemostasis
• Listing 7.17 Hematological Disorders Treated by Transplantation
• Listing 7.18 Repeated Complications
• Listing 7.02 Chronic Anemia (Historical Rule + Current Alternatives)

Frequently Asked Questions